Antiviral treatment with WIN 54 954 reduces mortality in murine coxsackievirus B3 myocarditis

被引:16
作者
Fohlman, J
Pauksen, K
Hyypia, T
Eggertsen, G
Ehrnst, A
Ilback, NG
Friman, G
机构
[1] TURKU UNIV, DEPT VIROL, TURKU, FINLAND
[2] KABI PHARMACIA AB, TOXICOL & SAFETY ASSESSMENT, HELSINGBORG, SWEDEN
[3] HUDDINGE UNIV HOSP, KAROLINSKA INST, DIV CLIN VIROL, S-14186 HUDDINGE, SWEDEN
[4] HUDDINGE HOSP, DIV CLIN CHEM, DEPT MED LAB SCI & TECHNOL, S-14186 HUDDINGE, SWEDEN
关键词
isoxazole; viruses; myocarditis; immunohistochemistry; cardiomyopathy;
D O I
10.1161/01.CIR.94.9.2254
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Coxsackieviruses B (CBVs) are dominant causative agents in myocarditis and are associated with pathogenesis in some cases of dilated cardiomyopathy, a clinical entity with a poor survival without heart transplantation. Methods and Results in vitro, the antiviral agent WIN 54 954 was shown to inhibit replication of CBV3 at a minimal inhibitory concentration value of 0.02 mg/L. Administration of WIN 54 954, 100 mg/kg BID PO, beginning on the day of infection resulted in complete protection from enteroviral mortality (P<.01). WIN 54 954 treatment did not abrogate the inflammatory reaction in the myocardium. No difference was found in the expression of surface lymphocyte subset markers. At 3 weeks, macrophages seemed to dominate the inflammatory reaction, regardless of treatment. There was no difference in CBV3 antibody titers, indicating that WIN 54 954 does not interfere with the development of protective immunity. Complement factors C3 and B were synthesized at a higher level during infection and correlated well with the degree of inflammatory reaction. Conclusions The results show that WIN 54 954 is a potent antiviral agent with a highly significant effect on survival in CBV-induced myocarditis in the A/J mouse if treatment is started early. It is suggested that the reduction in mortality seen with WIN 54 954 administration is due to an inhibitory effect on virus replication in affected organs that does not interfere with cellular or humoral immunity.
引用
收藏
页码:2254 / 2259
页数:6
相关论文
共 45 条
  • [1] SUPPRESSION OF COLDS IN HUMAN VOLUNTEERS CHALLENGED WITH RHINOVIRUS BY A NEW SYNTHETIC DRUG (R61837)
    ALNAKIB, W
    HIGGINS, PG
    BARROW, GI
    TYRRELL, DAJ
    ANDRIES, K
    VANDENBUSSCHE, G
    TAYLOR, N
    JANSSEN, PAJ
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1989, 33 (04) : 522 - 525
  • [2] ARCHARD LC, 1993, INT S CARD PATH MECH
  • [3] AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303
  • [4] STRUCTURAL-ANALYSIS OF A SERIES OF ANTIVIRAL AGENTS COMPLEXED WITH HUMAN RHINOVIRUS-14
    BADGER, J
    MINOR, I
    KREMER, MJ
    OLIVEIRA, MA
    SMITH, TJ
    GRIFFITH, JP
    GUERIN, DMA
    KRISHNASWAMY, S
    LUO, M
    ROSSMANN, MG
    MCKINLAY, MA
    DIANA, GD
    DUTKO, FJ
    FANCHER, M
    RUECKERT, RR
    HEINZ, BA
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1988, 85 (10) : 3304 - 3308
  • [5] DEBRUIJN MHL, 1985, P NATL ACAD SCI USA, V82, P708
  • [6] FALUS A, 1987, J IMMUNOL, V138, P856
  • [7] VACCINATION OF BALB/C MICE AGAINST ENTEROVIRAL MEDIATED MYOCARDITIS
    FOHLMAN, J
    ILBACK, NG
    FRIMAN, G
    MOREIN, B
    [J]. VACCINE, 1990, 8 (04) : 381 - 384
  • [8] A QUALITATIVE AND QUANTITATIVE METHOD FOR INSITU CHARACTERIZATION OF THE INFLAMMATORY RESPONSE IN EXPERIMENTAL MYOCARDITIS
    FOHLMAN, J
    FRIMAN, G
    ILBACK, NG
    AKESSON, A
    HUBER, S
    [J]. APMIS, 1990, 98 (06) : 559 - 567
  • [9] FRIMAN G, 1995, IN PRESS EUR HEART J
  • [10] GAUNTT C, 1993, SCAND J INFECT DIS, P49